RA Flashcards

1
Q

DEFINITION

A

RA is a chronic (life-long), systemic, autoimmune disease of unknown etiology that affects the diarthrodial (movable) joints, that involves an invasion of inflammatory cells into the synovium leading to synovial hyperplasia and edema called ‘pannus’.

PANNUS : Pannus is Latin for cloth or garment. In medicine, pannus is any abnormal tissue that: Contains blood vessels (necessary for tissue growth) Covers up a normal body structure.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

WHERE DOES IT AFFECT?

A

it affects mainly small and medium joints (of the hands and feet), and rarely large joints (e.g. shoulder, knee) and various organs, such as the lungs and vessels. Locally, inflammatory cells invade the synovium, otherwise relatively acellular, leading to hyperplasia and pannus formation that causes the damage of cartilage, erosion of bone and finally loss of function of the affected joint.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

the chronic inflammation favors …

A

an atherosclerotic process that puts these patients at high risk of myocardial infarctions and strokes at a much younger age relatively to the general population.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

PREVALANCE

A

● Prevalence - It is a very frequent disease. The most common polyarthritis (> 4 joints are involved) . The prevalence in western countries is 0.5-1% of the entire population. This means 1 or 2 people out of every 100 people.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

INCIDENCE

A

16.5 cases (〖10〗^5) for year in southern Europe, 29 cases in northern Europe and 38 cases in North America.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

SEX

A

RA is more prevalent in females (2.4:1), this ratio decreasing over time. The disease with highest emphasis on this difference is systemic lupus erythematosus where the ratio is 9:1.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

AGE

A

The peak of the gaussian curve of incidences is found between the 4th and 5th decade (midlife), however, the disease can be found at younger or older individuals. If the disease occurs before the age of 16y it is called ‘idiopathic juvenile arthritis’ (which will be covered in another lecture).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

MAIN CHARACTERISTICS

A
  1. Autoantibody production- 2 in particular:
    a. Rheumatoid factor- an IgM directed against the FC portion of IgGs.
    b. anti-citrullinated protein antibody (ACPA)
  2. Synovial inflammation and hyperplasia - giving rise to a ‘Pannus’ (swelling).
  3. Cartilage and bone destruction n- that occurs due to the inflammatory process. If the disease is not detected and treated appropriately it can cause permanent damage, deformity and disability.
  4. Systemic features - additional systemic features include cardiovascular, pulmonary and psychological and skeletal problems.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Etiology

A
  1. genetic background

– HLA-DRB1 SE allele
“Shared Epitope” (SE) = five amino acid sequence motif, of which 3 (residue 70, 71 and 74) are involved in the shaping of the peptide binding pocket 4 of the HLA molecule → MHC that binds citrullinated peptides with higher affinity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

etiology 2

A

B. Environmental Triggers

  1. Cigarette smoke
    - Increased risk of seropositive RA among subjects who had smoked ≥20 years
    - Evident at an intensity of smoking of 6-9 cigarettes/day (cumulative dose > risk)
    - Remained for up to 10-19 years after smoking cessation.
  2. Infection: periodontal infections ( Porphyromonas Gingivalis)
    This is the only bacterium that has a PAD enzyme (it’s called P-PAD) and therefore citrullinate proteins at their carboxy terminal arginine (while human PADs citrullinate the peptides within the peptide) → neoantigens → breakdown of tolerance

SHARED RISK FACTORS 🡪 cigarette smoke

PATHOLOGICAL SIMILARITIES 🡪 T cell activation, inflammatory cytokine profile, resultant bone destruction and deformity

These factors are involved in the breakdown of the tolerance to the ‘self’ molecules and the production of autoantibodies that will eventually lead to the clinical manifestations.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

autoantıbodies

A

Based on the presence of antibodies:
- seropositive (those positive for RF, ACPA or both)
- seronegative patients that have the clinical characteristics of RA but no autoantibodies (25%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

autoantibodies

A
  1. Rheumatoid factor
    - IgM directed against the Fc fragment of IgG
    - leads to formation of immune complexes → complement activation in the joints
    - increased vascular permeability
    - release of chemotactic factors
    - recruitment of immune effector cells
    - not very specific as it can be found in a number of other autoimmune disease (e.g. Sjogren syndrome, SLE), in other diseases (such as hepatitis) as well as is in normal healthy subjects (15%), mostly elderly
    - not very sensitive as it can be found in only about 60-70% of patients with RA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

autoantibodies 2

A

Anti-citrullinated protein antibodies (ACPA)
- very specific, as they can be found only in patients with RA
- not very sensitive as they can be found in only 70-80% of RA patients
- Negative predictive factor! → increased bone loss
- They define a subset of RA that differs in terms of pathogenesis, disease course and response to therapy when compared with ACPA-negative RA.
Citrullination is a post-translational process carried out by protein arginine deaminases (PADs): arginine → citrulline by the removal an amino group.
Proteins undergoing citrullination: vimentin, filaggrin, t2 collagen

N.B. ACPAs, RF can be present many years before disease onset, before any evidence of inflammation and immunity can be detected in the joints → RA begins outside of the joints (Lung - smoke, Periodontal - P.G.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Citrullination

A

Citrullination of proteins is a process that occurs almost exclusively in dying cells (apoptosis, autophagy, netosis, necrosis) when the cell membrane becomes leaky, allowing an unlimited influx of extracellular Ca2+ ions. This modification leads to conformational alteration, possible functional alteration, change in the protein half-life, and new epitopes generation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

autoantibodies 3

A
  1. Anti-CarP (Carbamylated Protein) antibodies - new class discovered in the last years
    - Carbamylation is a chemical modification of the molecules in the presence of cyanate
    - Proposed targets for these antibodies are: vimentin, albumin, fibrinogen β chain, α1 anti-trypsin.
    - Anti-CarP are found in about 45% of the patients with RA
    - Interestingly, Anti-CarP antibodies are actually found in the 30% of the seronegative patients
    - anti-CarP positivity is associated with a more erosive disease.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Clinical presentation

A
  1. Constitutional symptoms - just like other inflammatory arthritis, the initial onset could be accompanied by constitutional symptoms, including: fatigue, anemia, myalgia or weight loss.
17
Q

Clinical presentation 2

A
  1. Arthritis: pain, swelling and stiffness.
    - onset: insidious and gradual
    - polyarticular (>4 joints involved)
    - symmetrical
    - additive (when RA affects new joints, there’s no resolution in those previously involved)
    - centripetal
    - Main joints: PIPs, MCP and wrists, followed by MTP and IFP feet, knees, ankles
    - distal joints are spared
    - Axial joints: that could be affected are the 1st and 2nd intervertebral regions of the cervical spine at the level of the atlanto-axial joint (but the rest of the spine is spared) because those are the only joints of the spine with a synovial membrane.
    - This type of involvement could be very dangerous, because it might cause compression of the medulla oblongata.
18
Q

clinical presentation 3

A
  1. Bone erosion -> w/o treatment -> deformities and disabilities, treatment can prevent (goal)
    - develop more quickly in the early stages
    - (70% of the patients present bone erosions within 2 years after initial clinical manifestation, and 40% present erosion within 6 months from the disease onset)
    - mechanical factors predispose to erosion in particular joints (eg. II and III MCF).
19
Q

DEFORMITIES

A
  1. Volar subluxation - MCP Ulnar drift
    2.Boutinnere(proximal) and Swan neck(distal) deformity
    3.Plantar subluxation of metatarsal heads (Traingular forefoot)
    4.Z-deformity of the thumb
20
Q
  1. Systemic manifestations
A
  1. Rheumatoid nodules (15-20% of patients)
    - bony prominences along the tendons
    - indicative of the more severe disease (expression of vasculitis)
    - Central fibrinoid necrosis, with surrounding palisading histiocytes and an outer layer of chronic fibrosing connective tissue
21
Q

systemic 2

A
  1. Lung 67% - accounts for 10% to 20% of deaths
    - Interstitial lung disease (20-44% of patients)
    the most common forms are non-specific interstitial pneumonia (NSIP) with inflammation (cell infiltration) of the alveoli appearing as ‘ground glass’, and the usual interstitial pneumonia (UIP) with the honeycombing appearance, when the fibrosis is more established (more severe). ILD is an early and often asymptomatic finding in RA (clinically significant disease in 10-25% of pts). Asymptomatic ILD often precedes the articular manifestations of RA by months or years. The best way to assess the lung damage is by high resolution CT scan and pulmonary function tests. HLA-B54, HLA-B40, HLA-DQB10601, HLA-DRB11502, and HLA-DR4 have been associated with RA-ILD. Patients with RA-ILD have a 3-fold increased risk of death in comparison to those without ILD.
    - Lung nodules
    - Neoplasm and infection should be ruled out
    - multiple nodules suggests an underlying disease, while a solitary nodule is more suggestive of cancer. Sometimes a biopsy is required.
22
Q

systemic 3

A
  1. Vasculitis
    - small vessels. It can lead to fibrinoid necrosis.
  2. Eyes <1% of RA patients
    - Scleritis- the more severe form that presents as painful red eye🡪 a medical emergency.
    - Episcleritis- the less severe involvement, eye becomes red.
  3. Muscle Atrophy - atrophy of the interosseous muscles
  4. Renal amyloidosis (rare) - Creatinine levels increase slowly (normal levels: 0.9/1 mg/dl).
23
Q

systemic 4

A
  1. Felty’s syndrome - (rare 2-3%)
    - Clinical triad:
    a. chronic arthritis
    b. splenomegaly
    c. granulocytopenia (<2000/mm3
    → increased risk of developing infections.
24
Q

Causes of death

A

● Infections 2x risk due to: neutropenia, disruption of anatomical barrier, chronic inflamm, drug immunosup
● Atherosclerosis due to chronic inflammation and biologics
● Lymphoma

25
Q

DIAGNOSIS

A

Eular score > 6
1. Number of joints involved
- Large joints have a low score because RA is known to affect mostly the smaller joints.
2. Serology: presence of RF and ACPA
3. Inflammatory markers (CRP and ESR)
4. Duration of symptoms (6 weeks)

26
Q

LABS

A

Labs:
1. CBC- looking for anemia and thrombocytosis
2. Inflammatory markers- ESR and CRP
3. Autoantibodies

27
Q

IMAGING

A

Radiology:
1. X-ray
- bony erosions
- reduction in joint space (due to the loss of cartilage)
➢ obtain an X-ray at time zero as a frame of reference in the future, to which the follow up could be compared.

  1. CT scan (only in cases of a doubt regarding severity, where a change of therapy is at stake for a particular patient)
  2. US and Power Doppler
    - US: Fluid and the pannus proliferation
    - Doppler: angiogenesis as a marker of level of inflammation
28
Q

Severity/Activity Assessment

A
  1. Number of swollen joints (out of 28)
  2. Number tender joints (Ritchie Index)
  3. Patient’s global health assessment (1-100) in the past week
  4. Presence of acute phase reactants
    ● > 5.1 🡪 high activity
    ● 5.1-3.2 🡪 moderate
    ● 3.2-2.6 🡪 low
    ● < 2.6 🡪 remission
29
Q

TREATMENT GOALS

A

What is the goal of RA therapy?
- Early RA 🡪 full clinical remission / prevention of joint destruction 🡪 prevention of disability
- Established RA 🡪 Clinical improvement

30
Q

PHASE I

A

Phase I
1. DMARDs (immunosupression)
- Methotrexate 1st line
- if not well tolerated or contraindicated: other DMARDs such as Sulfasalazine or Leflunomide
- Check: LFT, CBC, pregnancy
and
2. Short-term glucocorticoids
- symptomatic releifs and improve the function, but no change in disease progression
- lowest dose and shortest term possible because of severe side effects

Then, patients should be monitored for 3 months:
if remission is achieved, continue with the treatment

31
Q

METHOTREXATE

A

METHOTREXATE
Antimetabolite
competitively inhibits dihydrofolate reductase and AICAR transformylase

32
Q

SULFASALAZINE

A

SULFASALAZINE
anti-inflammatory
pro-drug that is converted into the active metabolite, 5-aminosalicylic acid (5-ASA)

33
Q

LEFLUNOMIDE

A

LEFLUNOMIDE
reversibly inhibits dihydroorotate dehydrogenase → impaired pyrimidine synthesis → inhibition of T-cell proliferation